“PROTAC” modified dihydroquinolizinones (DHQs) that cause degradation of PAPD-5 and inhibition of hepatitis A virus and hepatitis B virus, in vitro
- 29 February 2024
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 102, 129680
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R21-AI163606)
- National Institutes of Health
This publication has 31 references indexed in Scilit:
- Antiviral PROTACs: Opportunity borne with challengeCell Insight, 2023
- Targeted protein degradation as an antiviral approachAntiviral Research, 2022
- Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infectionBioorganic & Medicinal Chemistry Letters, 2022
- Factors Associated With Hepatitis A Mortality During Person‐to‐Person Outbreaks: A Matched Case–Control Study—United States, 2016‐2019Hepatology, 2021
- Host RNA quality control as a hepatitis B antiviral targetAntiviral Research, 2021
- Efficacy of an Inhibitor of Hepatitis B Virus Expression in Combination With Entecavir and Interferon‐α in Woodchucks Chronically Infected With Woodchuck Hepatitis VirusHepatology Communications, 2020
- PAPD5/7 Are Host Factors That Are Required for Hepatitis B Virus RNA StabilizationHepatology, 2019
- HBsAg mRNA degradation induced by a dihydroquinolizinone compound depends on the HBV posttranscriptional regulatory elementAntiviral Research, 2018
- Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysisHepatology, 2015
- Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNACell, 1986